We describe the only case we are aware of where molecular analysis and in vitro high throughput drug screening (HTS) aided treatment decision making by suggesting resistance to conventional, yet toxic, treatment regimens and identified a tolerable, novel targeted therapy in a patient with ETV6‐MECOM fusion‐positive refractory AML. Here, MECOM is linked to acute myeloid leukemia.